San­doz opens two new fa­cil­i­ties; Gates Foun­da­tion funds nee­dle-free vac­cines; No­var­tis ex­pands Japan­ese site

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

San­doz in­au­gu­rat­ed two sep­a­rate fa­cil­i­ties in Aus­tria and Ger­many ded­i­cat­ed to the pro­duc­tion of peni­cillin and the de­vel­op­ment of biosim­i­lars, re­spec­tive­ly. The gener­ic drug­mak­er in­vest­ed €150 mil­lion ($163 mil­lion) in the Aus­tri­an site and €25 mil­lion ($27 mil­lion) in the Ger­man site. The open­ings “reaf­firm the dual San­doz com­mit­ment to en­sur­ing sus­tain­able ac­cess to qual­i­ty an­tibi­otics and spear­head­ing de­vel­op­ment of biosim­i­lars,” the com­pa­ny said in a Nov. 10 re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER